Roche: Polivy approved in Europe
(CercleFinance.com) - On Wednesday evening Roche announced that it has received a marketing authorisation in the European Union for its drug Polivy for the treatment of diffuse large B-cell lymphoma, a particularly aggressive form of blood cancer.
In a statement, the Swiss pharmaceutical company said that Brussels' green light covers the use of Polivy in combination with its blood cancer treatment MabThera, as well as the anticancer drug cyclophosphamide, the chemotherapy drug doxorubicin and the anti-inflammatory drug prednisone.
In phase III trials, this combination reduced the risk of disease progression or death in treated patients by 27%.
Polivy, an antibody drug, targets a protein specifically expressed in most B-cells, the immune cells affected in certain types of non-Hodgkin's lymphoma.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
In a statement, the Swiss pharmaceutical company said that Brussels' green light covers the use of Polivy in combination with its blood cancer treatment MabThera, as well as the anticancer drug cyclophosphamide, the chemotherapy drug doxorubicin and the anti-inflammatory drug prednisone.
In phase III trials, this combination reduced the risk of disease progression or death in treated patients by 27%.
Polivy, an antibody drug, targets a protein specifically expressed in most B-cells, the immune cells affected in certain types of non-Hodgkin's lymphoma.
Copyright (c) 2022 CercleFinance.com. All rights reserved.